Urology

PSA levels fall rapidly after surgery for benign prostate enlargement, with most patients reaching normal levels within 12 weeks, new research shows.

Patients under active surveillance for prostate cancer with low testosterone are more likely to experience ‘extreme’ disease progression, a 2026 study has found.

Surgical smoke from robot-assisted bladder cancer surgery showed no evidence of cancer cells, DNA mutations, or exosomes.

The Bellmunt Risk Score accurately predicts survival in metastatic castration-resistant prostate cancer, supporting its use in guiding treatment and risk stratification.

Virtual reality may help reduce patient anxiety, by giving people a better understanding of upcoming medical procedures, researchers reported today at EAU26.

Researchers reveal what matters most to patients with prostate cancer in treatment decisions at the Annual Congress of the European Association of Urology 2026.

With AI decision support, basic readers achieved efficiency scores comparable to expert radiologists, suggesting that AI may help standardise prostate cancer diagnosis across different levels of clinical expertise.

EAU 2026 data show prostate cancer screening has minimal impact on men’s quality of life and health anxiety, helping fill a key evidence gap for screening policy.